Aurinia制药 AUPH 深 沪
已收盘 09-05 16:00:00 美东时间
12.40
-0.130
-1.04%
华盛通- 最 高12.818
- 今 开12.56
- 成交量 182.51万股
- 最 低 12.36
- 昨 收 12.53
- 总市值 16.37亿
- 52周最高 12.818
- 市盈率 静 315.52
- 换手率 1.38%
- 52周最低 6.55
- 委 比 87.94%
- 总股本 1.32亿
- 历史最高 33.972
- 量 比 1.12
- 振 幅 3.66%
- 历史最低 1.41
- 每 手 1
- 风险率 1.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Aurinia Pharmaceuticals Raises FY2025 Sales Guidance from $250.00M-$260.00M to $260.00M-$270.00M vs $258.52M Est
Aurinia Pharmaceuticals (NASDAQ:AUPH) raises FY2025 sales outlook from $250.00 million-$260.00 million to $260.00 million-$270.00 million vs $258.52 million estimate.
07-31 18:01
Earnings Scheduled For July 31, 2025
Companies Reporting Before The Bell • Vanguard Extended Duration Treasury ETF (...
07-31 16:32
Here are the major earnings before the open Thursday
Major earnings expected before the bell on Thursday include: AbbVie (OTC:ABBY) Bristol-Myers Squibb Company (BMY) Mastercard Incorporated (MA) CVS Health Corporation (CVS) Shell plc (SHEL) Other earni...
07-31 06:00
HC Wainwright & Co. Assumes Aurinia Pharmaceuticals at Buy, Announces Price Target of $17
HC Wainwright & Co. analyst Arthur He assumes Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Buy rating and announces Price Target of $17.
07-30 19:12
美股周涨跌榜 | Blue Gold上市暴涨近10倍！脑再生科技反弹32%，指责卖空者导致股价巨震
金矿股Blue Gold上市暴涨近10倍！脑再生科技周内反弹32%，公司指责卖空者导致其股价剧烈波动>>
07-04 19:30
Aurinia Pharmaceuticals to Discuss AUR200 Phase 1 Study Results
Aurinia Pharmaceuticals ( ($AUPH) ) just unveiled an update. Aurinia Pharmaceut...
06-30 05:32
US Stocks Likely To Open On A Mixed Note: 'Nothing Good Happens Above A 5% Yield,' Says Expert
U.S. stock futures were fluctuating on Friday after a mixed close on Thursday. Futures of benchmark indices were mixed in premarket.
05-23 18:15
Aurinia Pharmaceuticals Q1 2025 Earnings: Strong Growth Amid Challenges
Aurinia Pharmaceuticals (($AUPH)) has held its Q1 earnings call. Read on for th...
05-13 08:24
Aurinia Pharma Swings Into Profit As Q1 Sales Jumps 24%, Sticks To Guidance
Aurinia posts Q1 profit and 25% LUPKYNIS sales growth, reports $62.47 million revenue, and reaffirms full-year guidance.
05-13 00:56
Aurinia Pharmaceuticals Affirms FY2025 Sales Guidance of $250.00M-$260.00M vs $257.87M Est
Aurinia Pharmaceuticals (NASDAQ:AUPH) affirms FY2025 sales outlook from $250.00 million-$260.00 million to $250.00 million-$260.00 million vs $257.87 million estimate.
05-12 18:03
